Abstract |
Ten outpatients meeting DSM-III-R criteria for obsessive-compulsive disorder completed a 32-week, open-label study with fluoxetine, a selective serotonin reuptake blocker. The patients were evaluated every four weeks for obsessive-compulsive symptomatology, anxiety, and depression. Significant improvement of obsessive-compulsive and anxiety measures were observed after four weeks, with maximal improvement at eight weeks. Depressed and nondepressed patients showed similar rates of improvement in obsessive-compulsive symptomatology. Overall, fluoxetine was tolerated well by all patients, and no serious side effects were observed. This study suggests that fluoxetine is an effective and safe treatment for obsessive-compulsive disorder, both for short-term alleviation and for long-term maintenance.
|
Authors | A Frenkel, J Rosenthal, A Nezu, A Winston |
Journal | The Mount Sinai journal of medicine, New York
(Mt Sinai J Med)
Vol. 57
Issue 6
Pg. 348-52
(Nov 1990)
ISSN: 0027-2507 [Print] United States |
PMID | 2079952
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Body Weight
- Female
- Fluoxetine
(administration & dosage, therapeutic use)
- Humans
- Male
- Obsessive-Compulsive Disorder
(drug therapy)
- Time Factors
|